Pulmatrix today presented data at the 2014 Respiratory Drug Delivery Conference in Fajardo, Puerto Rico. The poster presentation includes development data on PUR0400, a preclinical drug candidate of fluoroquinilone Levofloxacin formulated in the company’s proprietary iSPERSE™ dry powder technology.
Help employers find you! Check out all the jobs and post your resume.
